Coming to grips with hand-foot syndrome insights from clinical trials evaluating capecitabine

ONCOLOGY

Volumn 18, Issue 9, 2004, Pages 1161-1173

  Scheithauer, Werner ^a   Blum, Joanne ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE;

BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG ADMINISTRATION; ERYTHEMA; FEMALE; FOOT; HAND; HUMAN; MALE; PATIENT EDUCATION; REVIEW; SYNDROME;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; ERYTHEMA; FEMALE; FOOT; HAND; HUMANS; MALE; PATIENT EDUCATION; SYNDROME;

EID: 5644269852     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Zuehlke RL: Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 148:90-92, 1974.
2. Burgdorf WH, Gilmore WA, Ganick RG: Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 97:61-62, 1982.
3. Baack BR, Burgdorf WH: Chemotherapy-induced acral erythema. J Am Acad Dermatol 24:457-461, 1991.
4. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281, 1998.
5. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001.
6. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106, 2001.
7. Twelves C: Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 38(suppl 2):S15-S20, 2002.
8. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999.
9. Blum JL, Dieras V, Lo Russo PM, et al: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients. Cancer 92:1759-1768, 2001.
10. O'Shaughnessy J, Blum J, Moiseyenko V, et al: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247-1254, 2001.
11. Fumoleau P, Largillier P, Clippe C, et al: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536-542, 2004.
12. Maung K: Capecitabine/bevacizumab compared to capecitabine alone in pretreated metastatic breast cancer: Results of a phase III study. Clin Breast Cancer 3:375-377, 2003.
13. Reichardt P, von Minckwitz G, Thuss-Patience PC, et al: Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14:1227-1233, 2003.
14. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002.
15. Nagore E, Insa A, Sanmartín O: Antineoplastic therapy-induced palmar plantar erythrodysaesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 1:225-234, 2000.
16. Lokich JJ, Moore C: Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101:798-800, 1984.
17. Cohen PR: Acral erythema: A clinical review. Cutis 51:175-179, 1993.
18. Gordon KB, Tajuddin A, Guitart J, et al: Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75:2169-2173, 1995.
19. Levine LE, Medenica MM, Lorincz AL, et al: Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. Arch Dermatol 121:102-104, 1985.
20. Park YH, Ryoo BY, Lee HJ, et al: High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy. Ann Oncol 14:1691-1692, 2003.
21. de Vries EG, Greidanus J, Mulder NH, et al: A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin. J Clin Oncol 5:1445-1451, 1987.
22. Samuels BL, Vogelzang NJ, Ruane M, et al: Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep 71:971-972, 1987.
23. Hui YF, Cortes JE: Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. Pharmacotherapy 20:1221-1223, 2000.
24. Smith DH, Johnston SR, Gordon AN, et al: Economic evaluation of Doxil/ Caelyx vs topotecan for recurrent epithelial ovarian carcinoma: The UK perspective (abstract 808). Proc Am Soc Clin Oncol 20:203a, 2001.
25. Woll PJ, Carmichael J, Calvert AH, et al: Doxil/Caelyx (D) plus paclitaxel (T) in patients with metastatic breast cancer (MBCa): Update of a phase II efficacy and safety study (abstract 2017). Proc Am Soc Clin Oncol 20:67b, 2001.
26. Gallagher J: Management of cutaneous symptoms. Semin Oncol Nurs 4:239-247, 1995.
27. Zimmerman GC, Keeling JH, Burris HA, et al: Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 131:202-206, 1995.
28. Hoff PM, Valero V, Ibrahim N, et al: Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 82:965-969, 1998.
29. Rosner F: Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 83:1054-1055, 1998.
30. de Argila D, Dominguez JD, Iglesias L: Taxol-induced acral erythema. Dermatology 192:377-378, 1996.
31. Crider MK, Jansen J, Norins AL, et al: Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. Arch Dermatol 122:1023-1027, 1986.
32. Herzig RH, Wolff SN, Lazarus HM, et al: High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62:361-369, 1983.
33. Kroll SS, Koller CA, Kaled S, et al: Chemotherapy-induced acral erythema: Desquamating lesions involving the hands and feet. Ann Plast Surg 23:263-265, 1989.
34. Oksenhendler E, Landais P, Cordonnier C, et al: Acral erythema and systemic toxicity related to CHA induction therapy in acute myeloid leukemia. Eur J Cancer Clin Oncol 25:1181-1185, 1989.
35. Cortes JE, Kantarjian H, Garcia-Manero G, et al: A phase II study of troxacitabine, a novel nucleoside analog, in patients with leukemia (abstract 1212). Proc Am Soc Clin Oncol 20:304a, 2001.
36. Dent SF, Arnold A, Stewart D, et al: NCIC CTG IND 120: Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small cell lung cancer (NSCLC) (abstract 2786). Proc Am Soc Clin Oncol 20:259b, 2001.
37. Giles FJ, Garcia-Manero G, Cortes JE, et al: Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 20:656-664, 2002.
38. Moore MJ, Chi K, Ernst S, et al: A phase II study of troxacitabine in patients with advanced and/or metastatic renal cell carcinoma. NCIC CTG IND.119 (abstract 768). Proc Am Soc Clin Oncol 20:193a, 2001.
39. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998a.
40. Meta-analysis Group in Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 16:3537-3541, 1998b.
41. Jucgla A, Sais G, Navarro M, et al: Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol 131:364-365, 1995.
42. Bastida J, Diaz-Cascajo C, Borghi S: Chemotherapy-induced acral erythema due to Tegafur. Arch Derm Venereol 77:72-73, 1997.
43. Rivera E, Hyzinski M, Hutchins L, et al: A study of UFT + leucovorin (L) given as a three times daily (TID) regimen in the treatment of patients (Pts) with metastatic breast cancer (MBC) (abstract 1989). Proc Am Soc Clin Oncol 20:60b, 2001.
44. van Groeningen CJ, Peters GJ, Schornagel JH, et al: Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 18:2772-2779, 2000.
45. Elasmar SA, Saad ED, Hoff PM: Case report: Hand-foot syndrome induced by the oral fluoropyrimidine S-1. Jpn J Clin Oncol 31:172-174, 2001.
46. Baker SD, Diasio RB, O'Reilly S, et al: Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol 18:915-926, 2000.
47. Nemunaitis J, Eager R, Twaddell T, et al: Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors. J Clin Oncol 18:3423-3434, 2000.
48. Blum JL: The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6:56-64, 2001.
49. Pike K: Hand-foot syndrome. Oncol Nurs Forum 28:1519-1520, 2001.
50. Caelyx. (product monograph). Kenilworth, NJ: Schering-Plough Pharmaceuticals, 2000.
51. Uziely B, Jeffers S, Isacson R, et al: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785, 1995.
52. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001.
53. Doxil (prescribing information). ALZA Pharmaceuticals, Mountain View, Calif, 2001.
54. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 7:425-432, 1989.
55. Comandone A, Bretti S, La Grotta G, et al: Palmar-plantar erythrodysesthesia syndrome associated with 5-fluorouracil treatment. Anti-cancer Res 13:1781-1783, 1993.
56. Fabian CJ, Molina R, Slavik M, et al: Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 8:57-63, 1990.
57. Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with IV 5-fluorouracil/leucovorin. Capecitabine CRC Study Group. Ann Oncol 13:566-575, 2002.
58. Vail DM, Chun R, Thamm DH, et al: Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model. Clin Cancer Res 4:1567-1571, 1998.
59. Lauman MK, Mortimer J: Effect of pyridoxine on the incidence of palmar plantar erythroderma (PPE) in patients receiving capecitabine (abstract 1565). Proc Am Soc Clin Oncol 20:392a, 2001.
60. Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study. J Clin Oncol 13:2851-2855, 1995.
61. Olver IN, Aisner J, Hament A, et al: A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6:1732-1735, 1988.
62. Lopez AM, Wallace L, Dorr RT, et al: Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 44:303-306, 1999.
63. Chin SF, Tchen N, Oza AM, et al: Use of "Bag Balm" as topical treatment of palmar-plantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapeutic agents (abstract 1632). Proc Am Soc Clin Oncol 20:409a, 2001.
64. Coleman RL, Lin WM, Miller DS, et al: Oral dexamethasone (DMS) attenuates Doxil-induced palmar plantar erythema (PPE) in patients with recurrent gynecologic malignancies (abstract 883). Proc Am Soc Clin Oncol 20:221a, 2001.
65. Lyass O, Lotem M, Edelmann D, et al: Protective effect of amifostine (AMF) on Doxil/Caelyx-induced palmar-plantar erythrodysesthesia (PPE) in patients (pts) with advanced cancer (abstract 2148). Proc Am Soc Clin Oncol 20:99b, 2001.
66. Szumacher E, Wighton A, Franssen E, et al: Phase II study assessing the effectiveness of Biafine cream as a prophylactic agent for radiation-induced acute skin toxicity to the breast in women undergoing radiotherapy with concomitant CMF chemotherapy. Int J Radiat Oncol Biol Phys 51:81-86, 2001.
67. Kingsley EC: 5-Fluorouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med 120:813, 1994.
68. Peuckmann V, Fisch M, Bruera E: Potential novel uses of thalidomide: Focus on palliative care. Drugs 60:273-292, 2000.
69. Lin E, Morris JS, Ayers GD: Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology 16(12 suppl 14):31-37, 2002.
70. Lin E, Morris J, Chau NK, et al: Celecoxib attenuated capecitabine induced hand-and-foot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer (MCRC) (abstract 2364). Proc Am Soc Clin Oncol 21:138b, 2002.
71. Blum J, Jones S, Buzdar A, et al: Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated MBC: Updated results and analysis of dose modification (abstract 693). Eur J Cancer 37(suppl 6):S190, 2001b.
72. Hoff PM: Capecitabine as first-line treatment for metastatic colorectal cancer (CRC): Integrated results of 1201 patients (pts) from 2 randomized, phase III studies. On behalf of the Capecitabine CRC Study Group (abstract 263). Ann Oncol 11(suppl 4):60, 2000.
73. Nowacki M, Kröning H, Cervantes A, et al: Improved safety of capecitabine vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT phase III study). Eur J Cancer 1(suppl 5):S326, 2003.
74. Van Cutsem E, Twelves C, Tabernero J, et al: XELOX:Mature results of a mulitnational, phase II trial of capecitabine plus oxaliplatin, an effective first-line option for patients with metastatic colorectal cancer (abstract 1023). Proc Am Soc Clin Oncol 22:255, 2003.
75. Patt YZ, Lin E, Leibmann J, et al: Capecitabine plus irinotecan for chemotherapy-naive patients with metastatic colorectal cancer (MCRC): US multicenter phase II trial (abstract 1130). Proc Am Soc Clin Oncol 22:281, 2003.